Fig. 2From: In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PETa, b Representative BLI images of mice injected with MM.1S-CG and U266-CG cells, respectively (treated and untreated cohorts), showing systemic tumor progression and response to bortezomib therapy over time. c, d Percent increase in bioluminescence signal intensity showing tumor progression in treated and untreated cohorts plotted as a function of time (weeks post-tumor implantation)Back to article page